X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-06 | ATTO | Attovia Therapeutics, Inc. | Frazier Life Sciences Xi, L.P. | 10% | P - Purchase | $17.00 | +588,235 | 6,154,213 | +11% | +$9,999,995 | |||||
2026-08-04 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.25 | -30,000 | 6,188,287 | 0% | -$97,500 | ||||||
| D | 2026-08-05 | PCVX | Vaxcyte, Inc. | Dhaliwal Harpreet S. | Chief Technical Ops Officer | S - Sale+OE | $55.00 | -17,000 | 76,756 | -18% | -$935,068 | |||||
| D | 2026-08-03 | PCVX | Vaxcyte, Inc. | Wassil Jim | COO | S - Sale+OE | $53.86 | -2,250 | 157,541 | -1% | -$121,195 | |||||
| D | 2026-08-03 | PCVX | Vaxcyte, Inc. | Guggenhime Andrew | Pres, CFO | S - Sale+OE | $53.89 | -10,000 | 167,026 | -6% | -$538,879 | |||||
2026-08-04 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.23 | -26,842 | 844,895 | -3% | -$274,596 | ||||||
2026-08-03 | MAZE | Maze Therapeutics, Inc. | Coloma Jason V | CEO | S - Sale | $26.73 | -34,501 | 276,007 | -11% | -$922,315 | ||||||
2026-08-03 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $1.98 | -275 | 504,819 | 0% | -$544 | ||||||
2026-08-03 | EDIT | Editas Medicine, Inc. | Parison Amy | SVP, CFO | S - Sale | $2.58 | -678 | 14,292 | -5% | -$1,749 | ||||||
| D | 2026-08-03 | VCEL | Vericel Corp | Halpin Michael | COO | S - Sale+OE | $46.84 | -10,000 | 16,394 | -38% | -$468,400 | |||||
2026-08-03 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $85.32 | -2,888 | 269,678 | -1% | -$246,408 | ||||||
2026-08-03 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $85.32 | -1,133 | 119,281 | -1% | -$96,669 | ||||||
| D | 2026-08-03 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $85.32 | -5,101 | 818,938 | -1% | -$435,223 | |||||
2026-08-03 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $85.32 | -167 | 46,160 | 0% | -$14,249 | ||||||
2026-08-03 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $85.32 | -1,070 | 104,071 | -1% | -$91,294 | ||||||
2026-08-04 | FATE | Fate Therapeutics Inc | Tahl Cindy | See Remarks | S - Sale | $2.46 | -38,800 | 589,355 | -6% | -$95,405 | ||||||
| M | 2026-08-03 | BIIB | Biogen Inc. | Minor Lloyd | Dir | S - Sale | $202.15 | -1,186 | 2,689 | -31% | -$239,750 | |||||
2026-08-04 | FATE | Fate Therapeutics Inc | Valamehr Bahram | Pres, CEO | S - Sale | $2.46 | -43,947 | 591,815 | -7% | -$108,101 | ||||||
2026-08-03 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $130.31 | -15,000 | 592,133 | -2% | -$1,954,694 | ||||||
| M | 2026-07-31 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $8.00 | +52,900 | 3,148,223 | +2% | +$422,976 | |||||
2026-08-03 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $10.05 | -12,415 | 871,737 | -1% | -$124,722 | ||||||
2026-08-03 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Former Director | S - Sale | $9.58 | -10,000 | 131,633 | -7% | -$95,800 | ||||||
2026-07-30 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $24.00 | -1,299 | 399,989 | 0% | -$31,176 | ||||||
| M | 2026-07-29 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.96 | +45,768 | 18,489,293 | 0% | +$455,726 | |||||
| D | 2026-07-29 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | CSBO | S - Sale+OE | $27.34 | -7,500 | 26,250 | -22% | -$205,031 | |||||
2026-07-29 | DBVT | Dbv Technologies S.A. | Mohideen Pharis | Chief Medical Officer | S - Sale | $2.70 | -464 | 144,531 | 0% | -$1,253 | ||||||
| D | 2026-07-30 | VCEL | Vericel Corp | Siegal Jonathan | Principal Accounting Officer | S - Sale+OE | $48.90 | -4,500 | 1,078 | -81% | -$220,050 | |||||
| D | 2026-07-28 | NBIX | Neurocrine Biosciences Inc | Norwalk Leslie V | Dir | S - Sale+OE | $182.01 | -1,250 | 2,430 | -34% | -$227,508 | |||||
2026-07-28 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.61 | -1,459 | 158,285 | -1% | -$27,152 | ||||||
2026-07-28 | RLAY | Relay Therapeutics, Inc. | Rahmer Peter | See remarks | S - Sale | $18.61 | -748 | 228,165 | 0% | -$13,920 | ||||||
2026-07-28 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $18.61 | -2,237 | 407,660 | -1% | -$41,631 | ||||||
2026-07-29 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.78 | +5,000 | 373,885 | +1% | +$3,900 | ||||||
| D | 2026-07-27 | SCTX | Scribe Therapeutics, Inc. | Ah Bio Fund Ii, L.P. | 10% | P - Purchase | $15.00 | +333,333 | 3,082,725 | +12% | +$4,999,995 | |||||
| D | 2026-07-27 | SCTX | Scribe Therapeutics, Inc. | Gordon Carl L | Dir | P - Purchase | $15.00 | +1,000,000 | 1,348,825 | +287% | +$15,000,000 | |||||
| D | 2026-07-27 | SCTX | Scribe Therapeutics, Inc. | Orbimed Advisors LLC | Dir | P - Purchase | $15.00 | +1,000,000 | 1,348,825 | +287% | +$15,000,000 | |||||
2026-07-28 | EDIT | Editas Medicine, Inc. | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | S - Sale | $2.67 | -4,928 | 62,369 | -7% | -$13,158 | ||||||
2026-07-27 | BEAM | Beam Therapeutics Inc. | Simon Amy | Chief Medical Officer | S - Sale | $25.74 | -16,667 | 85,696 | -16% | -$429,037 | ||||||
2026-07-29 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Faisal Ghiath | Dir | P - Purchase | $1.05 | +95,398 | 220,972 | +76% | +$99,996 | ||||||
| M | 2026-07-24 | SCTX | Scribe Therapeutics, Inc. | Aghazadeh Behzad | See Remarks, 10% | P - Purchase | $15.16 | +2,391,238 | 3,088,888 | +343% | +$36,259,761 | |||||
2026-07-24 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.99 | +41,319 | 18,443,525 | 0% | +$412,777 | ||||||
| D | 2026-07-27 | PCVX | Vaxcyte, Inc. | Pickering Grant | CEO | S - Sale+OE | $55.63 | -18,198 | 586,462 | -3% | -$1,012,375 | |||||
2026-07-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $7.90 | +130 | 3,095,323 | 0% | +$1,027 | ||||||
| D | 2026-07-23 | SCTX | Scribe Therapeutics, Inc. | Lucas Svetlana | Chief Business Officer | P - Purchase | $15.00 | +3,000 | 3,000 | New | +$45,000 | |||||
| D | 2026-07-23 | SCTX | Scribe Therapeutics, Inc. | Parrot David | CFO | P - Purchase | $15.00 | +2,666 | 2,666 | New | +$39,990 | |||||
2026-07-23 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $93.89 | -2,238 | 272,566 | -1% | -$210,133 | ||||||
2026-07-22 | SRZN | Surrozen, Inc./De | Tcg Crossover Gp Ii, LLC | 10% | S - Sale | $21.25 | -325,000 | 574,047 | -36% | -$6,906,250 | ||||||
| D | 2026-07-24 | IMVT | Immunovant, Inc. | Pande Atul | Dir | S - Sale+OE | $39.80 | -1,500 | 136,731 | -1% | -$59,700 | |||||
2026-07-23 | IMVT | Immunovant, Inc. | Girao Tiago | CFO | S - Sale | $38.69 | -6,798 | 240,798 | -3% | -$263,015 | ||||||
2026-07-23 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $38.69 | -2,857 | 205,341 | -1% | -$110,537 | ||||||
| M | 2026-07-22 | DYAI | Dyadic International Inc | Francisco Trust Under Agreement Dated February 28, 1996 | 10% | S - Sale | $1.31 | -95,392 | 3,280,272 | -3% | -$124,958 | |||||
| M | 2026-07-22 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% | P - Purchase | $7.82 | +200,086 | 3,095,193 | +7% | +$1,565,499 | |||||
| M | 2026-07-21 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $9.76 | +264,586 | 18,402,206 | +1% | +$2,583,314 | |||||
| A | 2026-07-13 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $8.94 | +6,522 | 16,817,543 | 0% | +$58,307 | |||||
| D | 2026-07-21 | ADPT | Adaptive Biotechnologies Corp | Robins Harlan S | Chief Scientific Officer | S - Sale+OE | $21.89 | -492,400 | 812,058 | -38% | -$10,780,409 | |||||
2026-07-22 | GRML | Greenland Mines Ltd | Sawyer Jason David | Dir | P - Purchase | $0.23 | +240,000 | 240,000 | New | +$55,944 | ||||||
2026-07-21 | MGTX | Meiragtx Holdings Plc | Giroux Richard | CFO, COO | S - Sale | $12.51 | -56,000 | 998,682 | -5% | -$700,560 | ||||||
| D | 2026-07-16 | VOR | Vor Biopharma Inc. | Ra Capital Management, L.P. | 10% | S - Sale+OE | $19.75 | -213 | 4,501,882 | 0% | -$4,207 | |||||
| M | 2026-07-16 | IMA | Imagenebio, Inc. | Lally Robert B | Principal Accounting Officer | S - Sale | $5.42 | -3,196 | 55,582 | -5% | -$17,334 | |||||
2026-07-16 | ADPT | Adaptive Biotechnologies Corp | Bobulsky Susan | Chief Commercial Officer, MRD | S - Sale | $23.00 | -5,000 | 401,288 | -1% | -$115,000 | ||||||
| M | 2026-07-16 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $8.93 | +160,354 | 18,137,650 | +1% | +$1,432,119 | |||||
| D | 2026-07-17 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale+OE | $7.90 | -752 | 51,438 | -1% | -$5,943 | |||||
2026-07-17 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.83 | +500 | 368,885 | 0% | +$415 | ||||||
2026-07-20 | GRML | Greenland Mines Ltd | McGarity Jon | Dir | P - Purchase | $0.18 | +140,000 | 551,277 | +34% | +$24,822 | ||||||
| D | 2026-07-15 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $22.59 | -105,762 | 233,213 | -31% | -$2,389,164 | |||||
2026-07-16 | RGEN | Repligen Corp | Garland Jason K | CFO | S - Sale | $150.00 | -530 | 18,829 | -3% | -$79,500 | ||||||
| D | 2026-07-15 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $71.17 | -1,000 | 0 | -100% | -$71,170 | |||||
2026-07-16 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Pres, CEO | S - Sale | $23.18 | -9,500 | 585,038 | -2% | -$220,219 | ||||||
2026-07-16 | GRML | Greenland Mines Ltd | Leblanc Jeff | CFO | P - Purchase | $0.18 | +1,400,000 | 4,820,342 | +41% | +$245,280 | ||||||
2026-07-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $129.93 | -3,000 | 168,646 | -2% | -$389,777 | ||||||
2026-07-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Comm, Corp Aff Officer | S - Sale | $129.92 | -3,000 | 121,234 | -2% | -$389,758 | ||||||
| D | 2026-07-15 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $67.60 | -53,336 | 1,639,897 | -3% | -$3,605,514 | |||||
| D | 2026-07-15 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | COO | S - Sale+OE | $23.38 | -4,351 | 62,371 | -7% | -$101,730 | |||||
| D | 2026-07-14 | CRDF | Cardiff Oncology, Inc. | Pace Gary W | Dir | P - Purchase | $1.46 | +687,285 | 2,043,661 | +51% | +$1,000,000 | |||||
| D | 2026-07-14 | CRDF | Cardiff Oncology, Inc. | Mohindru Mani | CEO | P - Purchase | $1.46 | +34,364 | 59,067 | +139% | +$50,000 | |||||
| M | 2026-07-14 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.87 | +4,300 | 368,385 | +1% | +$3,754 | |||||
| M | 2026-07-10 | ARTV | Artiva Biotherapeutics, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $8.96 | +21,654 | 17,977,296 | 0% | +$194,040 | |||||
| M | 2026-07-09 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | See Remarks | S - Sale | $12.64 | -58,333 | 884,152 | -6% | -$737,410 | |||||
| D | 2026-07-10 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $75.16 | -24,165 | 0 | -100% | -$1,816,241 | |||||
| D | 2026-07-10 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $181.02 | -4,367 | 16,225 | -21% | -$790,514 | |||||
| D | 2026-07-09 | NBIX | Neurocrine Biosciences Inc | Lippoldt Darin | GC | S - Sale+OE | $179.60 | -10,000 | 54,729 | -15% | -$1,796,014 | |||||
2026-07-09 | TWST | Twist Bioscience Corp | Laponis Adam | CFO | S - Sale | $94.33 | -2,399 | 110,276 | -2% | -$226,307 | ||||||
| D | 2026-07-09 | CGEN | Compugen Ltd | Levine Zurit | SVP, Business Development | S - Sale+OE | $2.50 | -1,875 | 29,375 | -6% | -$4,688 | |||||
2026-07-08 | APGE | Apogee Therapeutics, Inc. | Henderson Michael Thomas | CEO | S - Sale | $133.63 | -20,000 | 920,941 | -2% | -$2,672,600 | ||||||
2026-07-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale | $6.24 | -200,000 | 936,410 | -18% | -$1,248,000 | ||||||
| M | 2026-07-08 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.96 | +7,500 | 369,485 | +2% | +$7,175 | |||||
| M | 2026-07-08 | PALI | Palisade Bio, Inc. | Baltera Robert Jr. | Dir | P - Purchase | $1.97 | +45,000 | 461,904 | +11% | +$88,698 | |||||
2026-07-08 | IMVT | Immunovant, Inc. | Gloria Melanie | COO | S - Sale | $39.55 | -2,036 | 222,357 | -1% | -$80,532 | ||||||
2026-07-08 | IMVT | Immunovant, Inc. | Van Tuyl Christopher | GC | S - Sale | $39.55 | -1,206 | 179,391 | -1% | -$47,702 | ||||||
2026-07-08 | IMVT | Immunovant, Inc. | Stout Jay S | CTO | S - Sale | $39.55 | -3,487 | 208,198 | -2% | -$137,925 | ||||||
| DM | 2026-07-07 | NBIX | Neurocrine Biosciences Inc | Delaet Ingrid | Chief Regulatory Officer | S - Sale+OE | $178.65 | -14,571 | 16,225 | -47% | -$2,603,112 | |||||
2026-07-07 | RXRX | Recursion Pharmaceuticals, Inc. | Borgeson Blake | Dir | S - Sale | $3.96 | -40,000 | 6,218,287 | -1% | -$158,500 | ||||||
| D | 2026-07-08 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $79.77 | -1,923 | 767,780 | 0% | -$153,391 | |||||
| M | 2026-07-06 | PALI | Palisade Bio, Inc. | Baltera Robert Jr. | Dir | P - Purchase | $2.04 | +50,000 | 416,904 | +14% | +$102,084 | |||||
| D | 2026-07-07 | PALI | Palisade Bio, Inc. | Jones Mitchell Lawrence | Chief Medical Officer | S - Sale+OE | $2.05 | -51,880 | 94,009 | -36% | -$106,536 | |||||
| D | 2026-07-07 | PALI | Palisade Bio, Inc. | Finley John David | CEO, CFO | S - Sale+OE | $2.07 | -146,798 | 217,739 | -40% | -$303,343 | |||||
2026-07-06 | RLAY | Relay Therapeutics, Inc. | Bergstrom Donald A | Pres, R, D | S - Sale | $18.71 | -8,660 | 409,897 | -2% | -$162,029 | ||||||
2026-07-07 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Pres, CEO | S - Sale | $19.58 | -48,199 | 1,502,801 | -3% | -$943,736 | ||||||
2026-07-06 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | CFO | S - Sale | $18.69 | -17,717 | 159,744 | -10% | -$331,131 | ||||||
2026-07-08 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $0.96 | +5,400 | 361,985 | +2% | +$5,208 | ||||||
2026-07-07 | MGTX | Meiragtx Holdings Plc | Naylor Stuart | CHIEF SCI OFCR, OPHTHALMOLOGY | S - Sale | $14.80 | -27,659 | 640,846 | -4% | -$409,470 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |